

REMARKS

Amendments: The specification has been amended to address the informalities noted by the Examiner on page 19. The claims have been amended to more specifically describe Examples III, IV and V. These amendments introduce no new matter.

35USC112, first paragraph - written description

Claims 19-29. The new claims specifically recite the natural NKG2D ligands MICA, MICB and ULBP, per Action, p.4, lines 5-6.

35USC112, first paragraph - enablement

Claims 18-38. The new claims specifically recite in vivo administration of NKG2D-ligand transduced cells, per Action, p.5, lines 13-15, and do not encompass NKG2D ligands in isolation or any NKG2D binding agent.

35USC112, second paragraph

Claims 19-38. The new claims reposition "expressing native NKG2D" to clarify that the tumor cells express the receptor, and the superfluous phrase "arising in situ" has been deleted.

The Examiner is invited to call the undersigned if she would like to amend the claims to clarify the foregoing or seeks further clarification of the claim language.

We petition for and authorize charging our Deposit Account No.19-0750 all necessary extensions of time. The Commissioner is authorized to charge any fees or credit any overcharges relating to this communication to our Dep. Acct. No.19-0750 (order B01-088).

Respectfully submitted,
SCIENCE & TECHNOLOGY LAW GROUP



Richard Aron Osman, J.D., Ph.D., Reg. No. 36,627
Tel: (650) 343-4341; Fax: (650)343-4342

"To Help Our Customers Get Patents"

Mission Statement, USPTO External Customer Services Guide